Arvinas, Inc. ARVN

ARVN Company Overview

Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) protein degradation technology. The company operates within the biopharmaceutical and biotechnology industries, with a primary emphasis on oncology and other serious diseases driven by pathogenic proteins that have historically been difficult to target with traditional small-molecule drugs.

Arvinas was founded in 2013 based on research from Yale University and has since positioned itself as a pioneer in targeted protein degradation. Unlike conventional inhibitors, PROTACs are designed to selectively tag disease-causing proteins for destruction by the cell’s natural protein disposal system. This approach is intended to address limitations of existing therapies, including drug resistance and incomplete target inhibition, and represents a differentiated strategy within precision medicine.